Page 13 - PRESENTATION

OS and PFS benefit with avelumab 1L maintenance

occurred irrespective of 1L chemotherapy regimen

Gemcitabine + cisplatin (N=389)

Median OS (95% CI), months Median PFS (95% CI), months

100 Avelumab + BSC 25.3 (18.6, NE) 100 Avelumab + BSC 4.6 (3.6, 6.8)
BSC alone 16.5 (13.4, 26.8) BSC alone 2.0 (1.9, 3.6)
90 90
HR 0.69 (95% CI, 0.51, 0.94) HR 0.63 (95% CI, 0.50, 0.81)
80 80
70 70
60 60
OS, % 50 PFS, % 50
40 40
30 30
20 20
10 10
0 0
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38
Months Months
No. at risk No. at risk
Avelumab +BSC 183 180 169 157 141 122 103 89 77 66 49 38 32 22 14 8 5 3 2 0 Avelumab +BSC 183 112 85 67 49 40 34 27 26 23 18 17 13 7 3 2 1 1 0
BSC 206 199 182 165 142 116 92 76 63 48 42 34 23 17 11 8 6 2 1 0 BSC 206 88 58 39 28 22 17 14 12 11 7 7 4 2 1 1 1 0

•NE, not estimable; PFS, progression-free survival
OS and PFS were measured post randomization (after chemotherapy) Grivas P, ESMO 2020